中文(ZH) 立方制药：取得美阿沙坦钾片药品注册证书

Lifang Pharmaceutical secures approval for hypertension drug

By PulseAugur Editorial · [1 sources] · 2026-05-22 10:39

Lifang Pharmaceutical has received approval from China's National Medical Products Administration for its Azilsartan Medoxomil Potassium tablets, indicated for treating adult primary hypertension. This marks a significant step for the company in the pharmaceutical sector. The approval covers both 40mg and 80mg dosages of the medication. AI

RANK_REASON Company received drug registration certificate from regulatory body. [lever_c_demoted from research: ic=1 ai=0.1]

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

How we ranked this

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Tool; Company received drug registration certificate from regulatory body. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration: Single-source cluster; Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics: product, other; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Low; Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness: 127 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

36氪 (36Kr) TIER_1 中文(ZH) · 2026-05-22 10:39

Cube Pharmaceuticals: Obtains Drug Registration Certificate for Azilsartan Medoxomil Potassium Tablets

36氪获悉，立方制药公告，公司收到国家药品监督管理局核准签发的美阿沙坦钾片（40mg、80mg）《药品注册证书》，该药品适用于治疗成人原发性高血压。